Drug Efficacy10 mg pilavapadin exhibited meaningful improvements from baseline in the Neuropathic Pain Symptom Inventory and the Patient Global Impression of Change scores, adding to pilavapadin's pain and quality of life benefits.
Financial PositionThe exclusive licensing agreement with Novo Nordisk significantly strengthens Lexicon's financial position, providing a cushion that should allow Lexicon to focus resources on pilavapadin's Ph.3 program in DPNP and the Ph.3 SONATA trial for sotagliflozin in Hypertrophic Cardiomyopathy.
Regulatory ProgressLexicon announced that additional data related to ZYNQUISTA’s benefit-risk profile in T1D have been submitted to the FDA, potentially supporting regulatory alignment.